key: cord-0877312-sw8bfe2c
authors: Kraynyak, Kimberly A; Blackwood, Elliott; Agnes, Joseph; Tebas, Pablo; Giffear, Mary; Amante, Dinah; Reuschel, Emma L; Purwar, Mansi; Christensen-Quick, Aaron; Liu, Neiman; Andrade, Viviane M; Diehl, Malissa C; Wani, Snehal; Lupicka, Martyna; Sylvester, Albert; Morrow, Matthew P; Pezzoli, Patrick; McMullan, Trevor; Kulkarni, Abhijeet J; Zaidi, Faraz I; Frase, Drew; Liaw, Kevin; Smith, Trevor R F; Ramos, Stephanie J; Ervin, John; Adams, Mark; Lee, Jessica; Dallas, Michael; Brown, Ami Shah; Shea, Jacqueline E; Kim, J Joseph; Weiner, David B; Broderick, Kate E; Humeau, Laurent M; Boyer, Jean D; Mammen, Mammen P
title: SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial
date: 2022-01-25
journal: J Infect Dis
DOI: 10.1093/infdis/jiac016
sha: 22cc074059d142226689fb79a89bd585d951467a
doc_id: 877312
cord_uid: sw8bfe2c

BACKGROUND: Additional SARS-CoV-2 vaccines that are safe and effective as primary vaccines and boosters remain urgently needed to combat the COVID-19 pandemic. We describe the safety and durability of the immune responses following two primary doses and a homologous booster dose of an investigational DNA vaccine (INO-4800) targeting the full-length spike antigen. METHODS: Three dosage strengths of INO-4800 (0.5 mg, 1.0 mg, and 2.0 mg) were evaluated in 120 age-stratified healthy adults. Intradermal injection of INO-4800 followed by electroporation at 0 and 4 weeks preceded an optional booster 6-10.5 months after the second dose. RESULTS: INO-4800 appeared well tolerated, with no treatment-related serious adverse events. Most adverse events were mild and did not increase in frequency with age and subsequent dosing. A durable antibody response was observed 6 months following the second dose; a homologous booster dose significantly increased immune responses. Cytokine producing T cells and activated CD8+ T cells with lytic potential were significantly increased in the 2.0 mg dose group. CONCLUSION: INO-4800 was well tolerated in a 2-dose primary series and as a homologous booster in all adults, including the elderly. These results support further development of INO-4800 for use as a primary vaccine and as a booster.

Primary safety endpoints included incidence of adverse events (AEs) using the "Toxicity 56 Vaccine was administered in 0.1 ml ID injections in the deltoid followed by EP at the injection 66 site. At each dosing visit, either a single injection for 0.5mg and 1.0mg dose groups or two 67 injections for 2.0mg dose group were given, one in each deltoid. 68 M a n u s c r i p t 9 Forty participants 18-50 years were enrolled sequentially into 1.0mg and 2.0mg dose groups 69 with a safety run-in period [14] . The trial design was expanded to include older participants in all 70 dosing groups (including a 0.5mg dose level). Upon favorable safety assessment review by an 71 independent Data Safety Monitoring Board (DSMB) of Week 1 data for 0.5mg dose group 72 participants aged 51-64 years and ≥ 65 years, enrollment of the corresponding age strata in the 73 1.0mg and subsequently 2.0mg dose groups was initiated. 74

Participants were assessed for safety (complete blood count, serum chemistry, and urinalysis), 75

including local and systemic AEs, at screening, Week 0 (Dose 1), next day phone call, and 76 A c c e p t e d M a n u s c r i p t 10 allergic reactions to vaccines or drugs; and medical conditions that increased risk for severe 91

Immunogenicity Assessment Methods 94

Samples were collected at timepoints described above with screening and pre-dose 1 samples 95 considered baseline. Peripheral blood mononuclear cells (PBMCs) were collected as previously 96 described [14] . After isolation, PBMCs were stored in the vapor phase of a liquid nitrogen freezer 97 until analysis, while serum samples were stored at -80°C. Eight participants were excluded from 98 the immunogenicity analyses due to a positive ELISA titer to the SARS-CoV-2 nucleoprotein, 99

suggesting SARS-CoV-2 infection 100 SARS-CoV-2 Pseudovirus Neutralization Assay: Serum samples were measured using a 101 pseudovirus neutralization assay as described previously [15] . Data was reported as ID 50 , which 102 is the reciprocal serum dilution resulting in 50% inhibition of infectivity by comparison to control 103 wells with no serum samples added. Supplementary methods show additional information. 104 SARS-CoV-2 Spike Enzyme-Linked Immunosorbent Assay (ELISA): Binding antibodies to 105 SARS-CoV-2 spike protein were measured by ELISA as described previously [15] . SARS-CoV-2 106 spike antibody concentrations were determined by interpolation from a dilution curve of SARS-107

CoV-2 convalescent plasma with an assigned concentration of 20,000 Units/mL. Supplementary 108 methods show additional information. 109

The SARS-CoV-2 spike antigen-specific IFN-γ 110 T-cell response was measured as described previously [14] . Values were reported as the mean was performed as previously described [14] . The LGL assay was also performed as reported 116

previously [18] following stimulation with overlapping peptides to the full-length spike protein to 117 measure CD8+T cell activation and capacity to produce lytic proteins. 118

No formal power analysis was applicable to this trial. Descriptive statistics were used to 120 summarize the safety endpoints based on the safety population: proportions of participants with 121

AEs, through 6 months following dose 2 (non-boosted participants) or 2 weeks following booster Between 06 April 2020 and 07 July 2020, 154 participants were screened and 120 enrolled into 132 the trial (Figure 1) Table 4) . 159 M a n u s c r i p t 13 

antibodies against SARS-CoV-2 following vaccination with INO-4800 was measured from sera. 162

The functionality of antibodies was assessed using a pseudovirus neutralization assay. All dose 163 groups induced neutralizing antibodies that peaked two weeks post second dose (GMTs-14. 

The contribution of SARS-CoV-2 specific CD4 + and CD8 + T cells was assessed by intracellular 203 cytokine staining (ICS) on participants following 2 doses, Figure 4B [19, 20] . Weaker inflammatory reactions consequent to 251 immunosenescence may explain the lower incidence of AEs among elderly participants [21, 22] . 252

Induction of both humoral and cellular responses were observed across all three dose groups, 253

inclusive of binding and neutralizing antibodies and cytokine producing T cells as well as 254 exhibiting lytic potential. Immunization with the 2.0 mg dose resulted in the highest GMTs of 255 neutralizing and binding antibodies as well as the highest magnitudes of IFN production to 256 M a n u s c r i p t 17 SARS-CoV-2 of any dose in all age groups tested, and the increases in antibody levels were 257 statistically significant above baseline at 6 months following dose 2. Importantly, increases in 258 both humoral and cellular immune responses were statistically significant following the booster 259

The contribution of the CD8+T cell response to vaccine efficacy has become increasingly 261 recognized as they have been detected early after vaccination [23] and due to their role in 262 controlling infection [24, 25] . Specifically, it has been established that CD8+T cells expressing 263 cytokines such as IFN and TNF as well as markers involved in activation status and 264 proliferation such as CD38 and Ki67 contribute to limiting disease severity during SARS-CoV-2 265

infection [24] . Additional studies have identified the expression of CD69 and CD137 on SARS-266

CoV-2 specific CD8+T cells being associated with less severe disease [25] . This expanded 267

CD8+T cells exhibiting these specific characteristics, suggesting the induction of a vaccine-269 induced cellular response that has potential to protect against severe COVID-19. As VoCs A c c e p t e d M a n u s c r i p t 31 Figure 5 

PhD, CMPP), the Wistar Institute

From Vaccine Nationalism to Vaccine Equity -Finding a Path Forward

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity

Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis

Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis

Immunogenicity of a DNA vaccine candidate for COVID-19

DNA vaccines: prime time is now

Addressing the Cold Reality of mRNA Vaccine Stability

A Comparison of Plasmid DNA and mRNA as Vaccine Technologies

Analysis of plasmid DNA from a pharmaceutical perspective

Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model

One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model

Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure. medRxiv : the preprint server for health sciences

Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine -Preliminary Report

Intradermal SynCon(R) Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers

Immune Therapy Targeting E6/E7 Oncogenes of Human Paillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis

Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials

Evaluation of the safety profile of COVID-19 vaccines: a rapid review

B-cell responses to vaccination at the extremes of age

Differential approaches for vaccination from childhood to old age

Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset

T cell responses in patients with COVID-19

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants

The investigators and sponsor express their gratitude for the contribution of all the trial participants and the invaluable advice of the independent Data Safety Monitoring Board. 

A c c e p t e d M a n u s c r i p t 21 A c c e p t e d M a n u s c r i p t